Companion Animal Diagnostics Market Size, Share & Trends Analysis Report, By Animal (Dogs, Cats, Horses), By Technology (Clinical Biochemistry), By Application, By End Use, By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global companion animal diagnostics market size was valued at USD 5.32 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2030. The growing adoption of pets in the U.S., Brazil, and China has increasingly driven demand for early detection, preventive care, and personalized treatment plans. This is aimed at combating the increasing prevalence of zoonotic diseases in pets. Veterinary diagnostics have played a crucial role in maintaining animal health.

The market demand was further surged by the increased animal health expenditure coupled with pet healthcare insurance. Proper pet diagnosis ensures timely treatment to prevent outbreaks, driving demand for veterinary care, pet insurance, medications, and more. Pet owners have increasingly adopted portable testing kits for inhouse testing while enables them to take informed decisions and seek veterinary assistance.

Furthermore, innovations in diagnostic technologies played a pivotal role in propelling market demand. Point-of-care portable diagnostics have gained major traction among pet owners as these allow rapid and accurate disease detection. Commercial availability of diverse reagents, test kits, and assays contributed to market growth as these can be conducted at various locations. In addition, major players including Idexx Laboratories have introduced product series and service enhancements. For instance, the VetConnect PLUS Mobile App and Catalyst SDMA-Based Test empower veterinary practices and initiate increased adoption.

Animal Insights

The dogs segment dominated the market in 2023 with a share of 46.8% in 2023 owing to the rising prevalence of zoonotic diseases, obesity, cancer, and skin disorders. A report by the American Veterinary Medical Association suggests that approximately 1 in 4 dogs develop neoplasia, and nearly 50% of dogs over 10 are affected by cancer. This underscores the significance of diagnostic services for effective canine health treatment. In addition, the increasing adoption of dogs as companion animals has augmented the growth as owners become increasingly aware of pet health and advancement in the veterinary healthcare sector.

The cats segment is expected to register the fastest-growing CAGR during the forecast period owing to the rising preference for cats as companion animals. Cats are the second most preferred companion animal after dogs as they offer emotional and psychological support to pet owners and are comparatively low maintenance.  As owners increasingly adopt cats, the market witnessed an increased awareness regarding pet health, diagnosis, and treatment. This prompted effective healthcare practices with innovative tools such as hematology analyzers, clinical biochemistry tests, and molecular diagnostics.

Technology Insights

Clinical biochemistry dominated the market in 2023 owing to the gradual prevalence of zoonotic diseases and conditions including diabetes, liver disorders, and kidney dysfunction. Pet owners have progressively recognized the benefits of clinical biochemistry for diagnosing and monitoring various health conditions in companion animals. These tests provide insights into organ function, metabolic status, and disease presence. Furthermore, the commercially available diverse reagents and consumables for clinical biochemistry have contributed to its prominence. The accuracy of these analyzers have encouraged both pet owners and veterinarians for rapid and efficient application.

The urinalysis segment is projected to grow at a CAGR of 9.5% during the forecast period owing to its rapidity, non-invasive nature, and on-site results that make it ideal for point-of-care diagnostics. These allow veterinarians to quickly assess kidney function, detect urinary tract infections, and monitor overall health. Additionally, innovations in urinalysis equipment including automated analyzers and dipstick-based tests simplify the process and allow timely diagnosis. This benefits both veterinary professionals and pet owners.

Application Insights

The clinical pathology segment accounted for the dominant market share with 34.6% in 2023 owing to the rising demand for comprehensive pet insurance. This trend has led to greater investment in diagnostic services, including clinical pathology to ensure early disease detection and effective treatment. Affordability and easy availability of clinical pathology tests further aid in the market growth of this segment. In addition, companion animals including cats and dogs are susceptible to various health conditions such as diabetes, and kidney disorders. Owners have increasingly resorted to clinical pathology for diagnosing and monitoring such chronic diseases. Moreover, the growing veterinary healthcare sector and the increase in the number of veterinary professionals have resulted in increased demand for clinical pathology labs and test kits.

Parasitology is anticipated to grow substantially over the forecast period. This market growth is attributed to the rise in parasitic diseases among the growing population of companion animals. The market saw a major rise in zoonotic illnesses caused due to parasites such as roundworms, tapeworms, hookworms, and more which led to a greater emphasis on parasitology testing.  Portable and rapid diagnostic equipment allows veterinarians to perform on-the-spot parasitology tests. These tests enable pet owners to seek essential and timely treatment of parasitic transmittable infections. Moreover, increased funding by major companies to develop effective and accurate drugs and treatments for parasitic illness has further contributed to the market growth.

End Use Insights

The veterinary diagnostic hospitals and clinics segment dominated the market in 2023 with a 28.4% share in 2023. Veterinary hospitals and clinics have embraced technological innovations, including point-of-care diagnostics (POCD). These advancements allow for faster and more accurate testing, enabling timely disease detection and treatment. For instance, the development of Symmetrical Dimethylarginine (SDMA) test kits with artificial intelligence (AI) for kidney function in dogs and cats has improved diagnostic capabilities. In addition, the growing awareness of zoonotic infections - diseases that can transfer between animals and humans, has increased. Veterinary diagnostic centers focus on detecting and managing such diseases, safeguarding both pets and their owners. Furthermore, international organizations, such as the OIE (World Organisation for Animal Health), have issued standards to enhance overall animal health and veterinary services. These guidelines have promoted investment in diagnostic infrastructure and contributed to market growth.

The point-of-care/in-house testing segment is expected to register the fastest CAGR during the forecast period owing to increased pet-related expenditures. As pet owners prioritize their companions’ health, there has been a surge in spending on veterinary services. Point-of-care testing, which provides rapid and convenient results directly at clinics or on-site, aligns with this trend. The convenience and speed of point-of-care testing benefits both veterinarians and pet owners. In addition, these tests cover a wide range of conditions, from clinical biochemistry to hematology, enhancing overall animal care.

Regional Insights

The North America companion animal diagnostics market held 49.1% of the global revenue share in 2023. This growth was augmented by the presence of major animal healthcare companies and the increasing companion animal population. These companies have primarily targeted to launch technologically advanced medical equipment to combat the rising animal disease diagnostic equipment and treatments.

U.S. Companion Animal Diagnostics Market Trends

The U.S. companion animal diagnostics held a substantial market share of 89.8% in the companion animal diagnostics market of North America due to the rising prevalence of chronic diseases such as diabetes, cancer, skin disorders, and more. The market has witnessed an increase in the practice of in-house testing coupled with the commercial availability of products related to diagnostics and treatment. Furthermore, growing disposable incomes have encouraged pet owners to invest in pet healthcare, driving demand for veterinary clinics, drugs, and treatments in the country.

Europe Companion Animal Diagnostics Market Trends

The Europe companion animal diagnostics market held a lucrative share of 24.2% in 2023. The market surge can be credited to the rising demand for veterinary clinics and diagnostic services. Key companies have invested in research and development efforts to launch efficient and technologically advanced drugs, test kits, and treatments.

Asia Pacific Companion Animal Diagnostics Market Trends

The Asia Pacific companion animal diagnostics market held 22.9% of the global revenue share in 2023. The region has witnessed a growing incidence of various animal diseases including parasitic infections and chronic conditions, which require timely treatment with accurate diagnostics. Furthermore, established diagnostic companies have significantly invested in research and development within the APAC market. Their presence, along with technological advancements, have driven enhanced diagnostic tools and services to meet the region’s needs.

The China companion animal diagnostics market dominated theAsia Pacific market in 2023. The developing veterinary healthcare sector and strong distribution channels in the country allowed key companies to improve their market penetration with new products. Furthermore, increasing awareness regarding animal healthcare and growing disposable income has resulted in the increased demand for companion animal diagnosis and treatment facilities.

Key Companion Animal Diagnostics Company Insights

Some of the major companies in the Companion Animal Diagnostics Market are Zoetis, BIOMÉRIEUX, Heska Corporation, IDEXX Laboratories, Inc., and more. Companies have focused on launching new and technologically advanced products with the help of increasing investments in research and development, collaboration, mergers, and acquisitions.

• IDEXX Laboratories, Inc. is a company that specializes in developing, manufacturing, and distributing products and services for companion animal veterinary, dairy market, livestock, poultry, and water testing. The company provides in-clinic laboratory analyzers for companion animal treatments.

• Zoetis is an animal health company that deals with the production and distribution of medicines and vaccinations for companion animals and livestock. They specialize in divisions such as pet care, equine, livestock, diagnostic, and more. 

Recent Developments

• In June 2024, IDEXX Laboratories, Inc. announced the launch of the Catalyst Pancreatic Lipase Test, a single-slide solution for dogs and cats suffering from pancreatitis. The innovative load-and-go workflow of the catalyst analyzers offers fast diagnosis helping in enhanced patient outcomes.

• In January 2024, Zoetis announced the expansion of its diagnostic platform, Vetscan Imagyst. The platform was upgraded with a new feature of AI Urine Sediment analysis. This feature enables veterinarians to collect accurate, in-clinic sediment analysis of fresh urine that will aid in making accurate treatment decisions. 

Companion Animal Diagnostics Market Report Scope

Global Companion Animal Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global companion animal diagnostics market report based on animal, technology, application, end use, and region:

• Animal Outlook (Revenue, USD Million, 2018 - 2030)

  • Dogs

  • Cats

  • Horses

  • Other Companion Animals

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinical Biochemistry

  • Immunodiagnostics

  • Hematology

  • Molecular diagnostics

  • Urinalysis

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Clinical Pathology

  • Bacteriology

  • Virology

  • Parasitology

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Diagnostic Laboratories 

  • Veterinary Hospitals and Clinics

  • Point-Of-Care/In-House Testing

  • Research Institutes and Universities

• Regional Outlook (Revenue, USD Million, 2018 - 2030) 

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait